In recent years, comparing to bio-pharmaceutical industries in Europe and America, the gap between China and those countries is not getting smaller and smaller, but even greater. From analysis research and development status of the international biotechnology drugs, it is not difficult to find that China doesn’t not seize the mainstream of international biopharmaceutical drugs. It even goes far away with the mainstream. To some extent, it reflects the Chinese pharmaceutical industry's future direction, and therefore it makes people worried.

About the latest research, in 2007, global pharmaceutical raw materials sales are expected to grow by 5 percent to 6 percent, from to 665 billion to $ 685 billion. Growth rate is less than 6 percent to 7 percent in 2006. Among them, the demand for biotech drugs is expected to grow strongly, the growth rate will reach 13% ~ 14%. 2004 to 2010, large pharmaceutical companies, bio-pharmaceutical sales compound annual growth rate is expected to reach 13%. Simultaneous growth and biological drugs, the rapid rise of the biotechnology, pharmaceutical raw materials. Biotechnology, bulk drugs and small molecule API market, which is mainly for internal use.

The development of the global biopharmaceutical industry is extremely uneven. First, the level of development of national bio-pharmaceutical industry is extremely uneven; biotechnology product’s development is highly uneven. The development of the biopharmaceutical industry depends primarily on the national scientific and technological strength and people's living standards. In 1993, North America (mainly USA), the biopharmaceutical industry in the European Union and Japan almost three pillars, each 20 to 30 billion U.S. dollars in the market share of a total of $ 8.4 billion. But after 10 years of development, the United States is far from other countries left behind their biotech drugs accounted for 58% of the global biopharmaceutical market, and this glutathione proportion is still expanding. The EU after the last five years of development, are catching up with the United States, its share reached 22%. Japanese biopharmaceutical development is lagging behind and even stagnation. Other countries and regions, the biopharmaceutical basically in its infancy.

Biopharmaceutical research, development and production of key technologies with the United States and other countries there is a considerable gap. According to statistics, 10 percent of biotech drugs accounted for 90% of the biopharmaceutical market. In the more than 500 biotechnology drugs approved by the U.S., EU and other major biopharmaceutical power listed, ranked in the top 10 kinds of product sales accounted for more than 50% of the biopharmaceutical market. The first 50 kinds of products of animal cell products in terms of quantity or from the sales point of view are accounted for around 65% to 70%.

Biomedical development shows the market concentration, product concentration of a significant trend, developed countries dominate. A few developed countries in the global biopharmaceutical market have dominant positions. The world pharmaceutical market, the United States, Europe, Japan's three major pharmaceutical market share exceeds 80%. From the biotechnology industry, global biotechnology company, the total number of 4362, total sales of approximately $ 41.3 billion, of which the total number of biotechnology companies mainly in Europe, accounting for 76% of the global total sales of U.S. and European companies accounted for the global biotechnology 93% of the company's sales, while sales in the Asia-Pacific region accounted for only about 3% of the world. The U.S. biotechnology industry leader, far ahead of other countries, the development of products and market sales account for more than 70 percent of the world.

Large multinational corporations dominate the world market for patent resveratrol medicine. The position of these multinational corporations in the global pharmaceutical market is increasingly rising, the proportion is growing. The global pharmaceutical 20 company sales income accounted for 50% of the global pharmaceutical market from 1994 to 2002, rising to 66%, the degree of concentration of the modern pharmaceutical industry is increasing year by year, the monopoly of multinational companies continue to increase.

In the field of product marketing, market concentration of single type sales also shows a constant increase trend. Total sales of world's top 10 selling drugs are nearly 40 billion RMB, accounting for 1/10 of annual global pharmaceutical sales. This market concentrating situation will not be changed in a short time.

Source:http://www.cospcn.com